Plethora was formed by Sir Chris in 2004 as a speciality pharmaceutical company focusing on novel approaches for treatment of a range of urological disorders. The company achieved spectacular growth following Sir Chris’s investment with the market capitalisation quadrupling in the 12 months of 2006 to $77m. Growth continued to increase and the company achieved a peak valuation of c$86m in 2007. The number of employees increased 10-fold from 7 to 72 in the 12 months of 2006.


The company was founded by Sir Chris and Neil Stafford to address those underserved areas of urology, with a strategy of extending the use of established licensed urology medicines and developing products that have reached at least Phase I clinical trials for application within the field of urology.

Plethora would add value by discovering and developing new urological applications and by taking them through Phase II proof of concept trials. Out-licensing or partnering deals were for some of the Phase III study projects.

Plethora developed a portfolio of six products in development and two that are being marketed through its own business, The Urology Company.